Frequently Asked Questions

As allogeneic therapies advance toward commercialization, donor selection is increasingly influencing manufacturing consistency, product quality, scalability, and long-term commercial viability. Organizations are moving beyond donor eligibility and exploring how donor characteristics impact manufacturing outcomes and therapeutic performance.

Donor variability can significantly impact process robustness, yield, expansion, and product quality. Many developers are now evaluating donor-derived starting material as a critical determinant of manufacturing success and are developing strategies to reduce variability before it impacts downstream operations.

Developers are increasingly studying links between donor characteristics, critical material attributes, potency, and final product quality. The goal is to identify predictive markers that can support more consistent manufacturing and product performance.

A scalable donor sourcing strategy balances donor availability, quality, recallability, qualification, and long-term supply security. As allogeneic programs mature, sourcing strategies are becoming an increasingly important factor in manufacturing reliability and commercial readiness.

While early-stage programs often rely on broader donor acceptance criteria, commercial-stage therapies typically require enhanced characterization, traceability, qualification, and control of donor-derived starting materials to satisfy regulatory and quality expectations.

A fit-for-purpose donor possesses attributes that support the intended manufacturing, functional, and clinical requirements of a therapy. Defining these characteristics early can help improve consistency, reduce risk, and strengthen development strategies.

Strategies include enhanced donor characterization, predictive screening, donor qualification frameworks, improved sourcing models, and greater understanding of the relationship between donor attributes and manufacturing outcomes.

Cell source selection affects manufacturing workflows, supply chain requirements, product quality, scalability, regulatory considerations, and cost of goods. Selecting the appropriate starting material strategy is increasingly viewed as a key development decision rather than a purely operational one.

The summit is designed for professionals responsible for donor-derived starting material strategy, manufacturing performance, product quality, and scalability across allogeneic cell therapy development, including:

• Manufacturing & Technical Operations
• MSAT & Process Development
• Analytical Development
• Quality & Regulatory Affairs
• Supply Chain & Procurement
• Translational Sciences
• Cell Therapy Research & Development
• Cell Sourcing & Donor Management

Attendees join to benchmark donor qualification, donor characterization, sourcing, variability management, and commercialization strategies with peers tackling the same challenges.

Attendees will gain practical insights into donor characterization, donor qualification, donor sourcing, donor variability management, and cell source selection strategies that support more consistent, scalable allogeneic cell therapy development.

Through case studies, panel discussions, and peer-led presentations, attendees will explore how leading developers are improving starting material quality, reducing donor-driven manufacturing variability, strengthening donor sourcing strategies, and building commercially scalable cell therapy platforms.

The Donor Selection & Cell Source Summit is the only industry-focused forum dedicated to the donor selection, donor qualification, and cell sourcing decisions underpinning successful allogeneic cell therapy development.

Unlike broader cell therapy conferences, this meeting brings together manufacturing, technical operations, analytical development, quality, regulatory, supply chain, and translational science leaders to tackle one of the industry's most pressing challenges: how to improve product consistency, manufacturing performance, and scalability through better donor-derived starting material strategies.